×
News Home

Celldex Therapeutics, Inc. (CLDX) Stock Loses -15.34% This Week; Should You Buy?

Friday, December 04, 2020 11:42 AM | InvestorsObserver Analysts
Celldex Therapeutics, Inc. (CLDX) Stock Loses -15.34% This Week; Should You Buy?

Celldex Therapeutics, Inc. (CLDX) stock is up 652.34% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CLDX stock a score of 72 out of a possible 100.

That rank is mainly influenced by a long-term technical score of 90. CLDX's rank also includes a short-term technical score of 67. The fundamental score for CLDX is 59. In addition to the average rating from Wall Street analysts, CLDX stock has a mean target price of 26.333. This means analysts expect the stock to rise 36.72% over the next 12 months.

Overall Score - 72
CLDX has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on CLDX!

What's Happening with CLDX Stock Today

Celldex Therapeutics, Inc. (CLDX) stock has fallen -2.73% while the S&P 500 is up 0.68% as of 11:40 AM on Friday, Dec 4. CLDX is down -$0.54 from the previous closing price of $19.80 on volume of 176,937 shares. Over the past year the S&P 500 has gained 18.42% while CLDX is up 652.34%. CLDX lost -$2.22 per share in the over the last 12 months.

Click Here to get the full Stock Score Report on Celldex Therapeutics, Inc. (CLDX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App